Gut microbiota-dependent Trimethylamine-N-oxide (TMAO) has been reported to be strongly linked to renal function and to increased cardiovascular events in the general population and in Chronic Kidney Disease (CKD) patients. Considering the lack of data assessing renal handling of TMAO, we conducted this study to explore renal excretion and mechanisms of accumulation of TMAO during CKD. We prospectively measured glomerular filtration rate (mGFR) with gold standard methods and plasma concentrations of trimethylamine (TMA), TMAO, choline, betaine, and carnitine by LC-MS/MS in 124 controls, CKD, and hemodialysis (HD) patients. Renal clearance of each metabolite was assessed in a sub-group of 32 patients. Plasma TMAO was inversely correlated with mGFR ( = 0.388, < 0.001), confirming elevation of TMAO plasma levels in CKD. TMAO clearances were not significantly different from mGFR, with a mean ± SD TMAO fractional excretion of 105% ± 32%. This suggests a complete renal excretion of TMAO by glomerular filtration with a negligible participation of tubular secretion or reabsorption, during all stages of CKD. Moreover, TMAO was effectively removed within 4 h of hemodiafiltration, showing a higher fractional reduction value than that of urea (84.9% ± 6.5% vs. 79.2% ± 5.7%, = 0.04). This study reports a strong correlation between plasma TMAO levels and mGFR, in CKD, that can be mainly related to a decrease in TMAO glomerular filtration. Clearance data did not support a significant role for tubular secretion in TMAO renal elimination.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891811PMC
http://dx.doi.org/10.3390/toxins11110635DOI Listing

Publication Analysis

Top Keywords

glomerular filtration
16
tmao
13
chronic kidney
8
kidney disease
8
filtration rate
8
renal excretion
8
plasma tmao
8
ckd tmao
8
tmao glomerular
8
tubular secretion
8

Similar Publications

Background: With the emerging role of the blood biomarkers in Alzheimer's Disease (AD) clinical practice and trials, it is crucial to identify and address factors influencing the concentrations of these biomarkers in circulation for enhanced clinical utility. We aim to assess the impact of lung function on plasma AD biomarker levels and elucidate the relationship between lung function and Alzheimer's Disease and Related Dementias (ADRD).

Method: We used the Peak Expiratory Flow (PEF), plasma biomarkers of AD (Amyloid beta 42/40 (Aβ42/40) ratio, phosphorylated-tau181 (p-tau181), Neurofilament light chain (NfL) and Glial fibrillary acidic protein (GFAP)) measured in the Health and Retirement Study (HRS) 2016 survey participants (n = 3801) and incident dementia (n = 142) over 4 years.

View Article and Find Full Text PDF

Objectives: To examine the association between the age at onset of diabetes and the risk of all-cause mortality in a population of individuals diagnosed with type 2 diabetes mellitus (T2DM) and to identify risk factors associated with all-cause mortality in young-onset T2DM (YOD) patients in China.

Methods: This study utilized a cohort of 9759 patients who were diagnosed with T2DM and who were registered and enrolled in the National Basic Public Health Service Management Program in Qinghe District (now Qingjiangpu District) and Huai'an District, Huai'an City, Jiangsu Province, China. The patients were observed from November 2013 to July 2014, and all-cause mortality data were obtained by comprehensive matching with the Huai'an City Resident Mortality Database as of December 31, 2019.

View Article and Find Full Text PDF

Introduction: This study systematically examines the effects of chronic oral methadone use on the glomerular filtration rate (GFR) in patients participating in methadone maintenance therapy (MMT) in Qazvin City, Iran. Methadone, a synthetic -opioid receptor agonist, is predominantly utilized for the management of opioid dependence and pain relief; however, there is growing concern regarding its potential nephrotoxic effects.

Methods: An observational cross-sectional study was executed involving 150 participants who had been on methadone syrup for a minimum duration of 2 years.

View Article and Find Full Text PDF

Chronic kidney disease (CKD) stands as a formidable global health challenge, often advancing to end-stage renal disease (ESRD) with devastating morbidity and mortality. At the central of this progression lies podocyte injury, a critical determinant of glomerular dysfunction. Compound K (CK), a bioactive metabolite derived from ginsenoside, has emerged as a compelling candidate for nephroprotective therapy.

View Article and Find Full Text PDF

Background: Despite of long-lasting tolvaptan treatment, individual renal outcomes are unclear in autosomal dominant polycystic kidney disease (ADPKD). This post-hoc analysis of the TEMPO 3:4 trial aimed to evaluate the predictability of estimated height-adjusted total kidney volume growth rate (eHTKV-α) on renal outcomes.

Methods: In TEMPO 3:4, 1445 patients with ADPKD were randomised to tolvaptan or placebo for 3 years.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!